Detalhe da pesquisa
1.
Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.
Diabetes Obes Metab
; 26(6): 2390-2400, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38477183
2.
PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness.
BMJ Open Diabetes Res Care
; 8(1)2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32900698
3.
Viable podocyturia in healthy individuals: implications for podocytopathies.
Am J Kidney Dis
; 64(6): 1003-5, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25304982
4.
PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment.
BMJ Open Diabetes Res Care
; 4(1): e000216, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27486519
5.
Inhibition of MAP-kinase cascade normalizes the proliferation rate of fibroblasts from patients with Type 1 diabetes and nephropathy.
J Diabetes Complications
; 19(5): 291-6, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16112505